NovaGo Therapeutics Patent Portfolio Analysis

Money arrives before a single grant

A $29.7M Series B from the Swiss Paraplegic Foundation, Neurimmune Holding and Pureos Bioventures. The company was founded in Switzerland in 2015 and works on human antibody therapeutics intended to promote regeneration after cerebral stroke. That is a long runway between incorporation and a raise of this size, and it is worth asking what the investors were underwriting when they signed.

Not a granted patent. There are none. The whole published record consists of two families, both pending, filed under titles that name the target directly: anti-Nogo-A antibodies, methods for treating neurological disorders using them, and novel antibodies for neural repair and treatment of stroke. What the money bought was a position that has not yet been tested by an examiner's final word.

Everything sits on the pending side

Zero granted. Two published and pending. The first of those could grant at any time, and the realistic landing zone for first grants is around 2026. Until then nothing in this portfolio is enforceable, which is a plain statement of fact rather than a criticism. Most biotech records at this stage look exactly like this, because the science moves faster than any patent office.

The dates are the interesting part. One filing in 2020, one in 2025. Five years of silence in between, then a second family arriving in the same year the company is staffing up with a research scientist in biochemistry and cell biology. Read together, that pattern suggests the 2020 family carries the foundational claim and the 2025 filing builds on something learned since.

The entire position is a promise with a 2026 delivery date.

Nine names, and nobody on both

Nine inventors are named across two families. Combaluzier Benoit appears on one of the two. So do Andreas Maurer Michael and Paulo Morawski Vianna Eduardo. There is no single figure whose name runs through the whole record, no central architect binding the 2020 work to the 2025 work in the way small biotech portfolios usually reveal one.

That reads as two distinct pieces of work rather than one idea refined twice. Nine people on two families is a dense authorship for such a short record, and it points to a group large enough to run parallel threads. For a company with one open bio and clinical role, the inventor list is the clearest available picture of how much bench capacity sits behind those filings.

The neighbourhood is extremely well settled

The claims cluster in C07K, peptides and antibodies. Over the last five years the same CPC groups drew Regeneron Pharma with 351 families, Hoffmann La Roche with 306, Genentech with 271, Janssen Biotech with 261, Amgen with 206 and Novartis with 195. Against those numbers, two families is a rounding error. Anyone measuring this portfolio by volume will reach a conclusion in about four seconds.

Volume is the wrong measure here. In a class this populated, the count tells you how many people are working nearby, not who holds what. What matters is the precise scope of the claims that survive prosecution, and whether the anti-Nogo-A target space inside that vast class is as occupied as the class as a whole. Those are different questions with potentially different answers.

Two citations from an unexpected direction

Staidson Beijing Biopharmaceuticals cites the portfolio once. Tianjin Long And Biotechnology Company cites it once. Neither is among the large filers in the same CPC groups. Two citations is a small number, and a single citation from any one organisation proves nothing on its own about commercial intent. But it does prove the filings are being read by working groups outside Switzerland.

Citations are the earliest external confirmation that a claim sits somewhere other people want to stand. When they arrive from Chinese biopharma rather than from Regeneron or Roche, the signal is about where the follow-on work is happening. For a portfolio with nothing granted, being found at all is more information than the raw count suggests.

Two citations is thin evidence, and it is still evidence.

What the next twelve months decide

Here is the position stated plainly. NovaGo has money, a named target, nine inventors and a five-year gap that suggests patience rather than drift. What it does not have is a single enforceable claim. Everything rests on how much scope survives prosecution of the 2020 family, and the answer to that arrives around 2026, not before.

The filing geography adds a wrinkle. The record shows filings in BR and WO. A WO application is a door held open, not a national right, and the choice of which national phases to enter says more about commercial intent than any press release does. That choice, and the shape of the first allowed claims, are the two facts worth waiting for.